Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Lowered to $398 at Needham & Company

October 19, 2021 6:07 AM
Needham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $398.00 (from $400.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles